Betamethasone Versus Ketorolac Injection for the Treatment of DeQuervains Tenosynovitis

OrthoCarolina Research Institute, Inc.

Status and phase

Completed

Phase 4

Conditions

DeQuervain Tendinopathy

Treatments

Drug: Ketorolac

Drug: betamethasone

Study type

Interventional

Funder types

Other

Identifiers

NCT02604537

15060

Details and patient eligibility

About

The purpose of this study is to determine if corticosteroid injection modifies the natural course of de Quervain tendinopathy compared to a toradol injection.

Full description

If steroids are effective for Dequervain tenosynovitis because of their anti-inflammatory properties, then there is a reasonable and rational argument to be made for the local injection of NSAIDS (non-steroidal anti-inflammatory drugs) into the first dorsal extensor compartment. Ketorolac is an NSAID that has been proven efficacious in the treatment of another musculoskeletal condition. Moreover, compared to betamethasone (or other injectable corticosteroids), injection of ketorolac decreases the patient exposure to the potential side-effects of corticosteroids, especially that of elevation of blood sugar levels in diabetics.

Enrollment

64 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of DeQuervain tendinopathy
Understands the local language and is willing and able to follow the requirements of the protocol
Understands the informed consent and signs the institutional review board/independent ethics committee (IRB/IEC) approved informed consent form

Exclusion criteria

Patients who have an allergy to lidocaine, celestone, or ketorolac, nonsteroidal anti-inflammatory drugs (NSAIDs), or acetylsalicylic acid (ASA)
Patients who have an adverse reaction to lidocaine, celestone, or ketorolac (such as severe elevation of blood sugars in diabetics that caused medical complication)
Patients who have received a prior steroid injection within the past three months
Patients who have had a prior ipsilateral surgery for DeQuervain Tenosynovitis
Patients that have a skin lesion at the location of injection (such as trauma, eczema, rash)
Patients who have a current infection at the location of injection
Patients who have had iontophoresis within three months
Patients who are breast feeding, pregnant, or who plan to become pregnant in the next six months